Star Sports Medicine Co Ltd (Ticker: 1609 HK) is a China-based medical device company specializing in clinical sports medicine solutions. Star Sports Medicine plans to list on the Hong Kong Stock Exchange on May 5, 2026, planning to offer 8.42 million shares at a price of HKD 98.50, raising HKD 829.55 million (USD 105.88 million). The company is expected to have a market capitalization of USD 689.37 million at the time of the IPO.

According to the prospectus, Star Sports Medicine plans to use the IPO proceeds for research and development, product capacity expansion, brand promotion, business development, working capital, and strategic acquisitions. As reported in the prospectus, the company offers holistic solutions for the treatment of injuries to soft tissues, including rotator cuffs, ligaments, and meniscus. Reportedly, it is the largest domestic sports medicine implants and instruments provider in China, holding an approximate 6.5% market share. The offering is structured as an H Share listing. CCB International Capital and CITIC Securities are serving as the joint sponsors for the deal, alongside other joint managers including CLSA, CMBC Securities, and China Galaxy International.